The use of transcriptomic biomarkers for personalized medicine

Bettina Heidecker, Joshua M. Hare

Research output: Contribution to journalArticlepeer-review

45 Scopus citations


Microarrays are a high throughput technology that allows the quantification of tens of thousands of RNA transcripts in a single reaction. This new technology offers the promise of comprehensive study of disease at a genomic level, potentially identifying novel molecular abnormalities, developing novel clinical biomarkers, and investigating drug efficacy. The ability to develop a molecular profile corresponding to a therapeutic effect is the basis for the concept of drug repositioning. With regard to prediction of clinical events, microarray technology has the potential to contribute to the development of sophisticated new biomarkers useful as predictors of disease etiology, outcome, and responsiveness to therapy'so-called personalized medicine. Currently progress in the field is hampered by a degree of skepticism about the reliability of microarray data and its relevance for clinical applications. Here we discuss possible pitfalls of transcriptomic analysis, review current developments in the cardiovascular area and address the use of transcriptomics for clinical applications.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalHeart Failure Reviews
Issue number1
StatePublished - Mar 2007
Externally publishedYes


  • Biomarker
  • Microarray
  • Molecular signature
  • Pharmacogenomics
  • Transcriptome

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'The use of transcriptomic biomarkers for personalized medicine'. Together they form a unique fingerprint.

Cite this